Commonwealth Equity Services, Llc reports 6.12% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

US ˙ NasdaqCM ˙ US14888U1016

Security	CPRX / Catalyst Pharmaceuticals, Inc.
Institution	Commonwealth Equity Services, Llc
Latest Disclosed Ownership	16,080 shares
Latest Disclosed Value	$ 375,308

On February 12, 2026 - Commonwealth Equity Services, Llc filed a 13F-HR form disclosing ownership of 16,080 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $375,307 USD as of December 31, 2025. The entity filed a previous 13F-HR on October 22, 2025 disclosing 15,153 shares of Catalyst Pharmaceuticals, Inc.. The current value of the position is $503,143 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-02-12	2025-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	16,080	927	6.12	375		0.0005
2025-10-22	2025-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	15,153	-22,549	-59.81	0		0.0004
2025-08-06	2025-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	37,702	-3,873	-9.32	1	-100.00	0.0011
2025-05-09	2025-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	41,575	2,244	5.71	1		0.0014
2025-02-10	2024-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	39,331	22,455	133.06	1		0.0012
2024-10-18	2024-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	16,876	-2,023	-10.70	0		0.0005
2024-07-31	2024-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	18,899	-684	-3.49	0		0.0005
2024-04-29	2024-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	19,583	-638	-3.16	0		0.0005
2024-02-06	2023-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	20,221	3,041	17.70	0		0.0006
2023-10-23	2023-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	17,180	-6,824	-28.43	0		0.0004
2023-08-10	2023-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	24,004	3,360	16.28	0		0.0007
2023-05-11	2023-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	20,644	408	2.02	0		0.0007
2023-02-07	2022-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	20,236	4,318	27.13	0	-100.00	0.0009
2022-11-14	2022-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	15,918	2,233	16.32	204	114.74	0.0005
2022-07-19	2022-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	13,685	2,885	26.71	95	6.74	0.0002
2022-05-04	2022-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	10,800	-2,055	-15.99	89	2.30	0.0002
2022-01-31	2021-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	12,855	641	5.25	87	35.94	0.0002
2021-10-29	2021-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	12,214	1,158	10.47	64	1.59	0.0002
2021-08-11	2021-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	11,056	0	0.00	63	26.00	0.0002
2021-05-04	2021-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	11,056	-1,259	-10.22	50	21.95	0.0001
2021-02-11	2020-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	12,315	-1,000	-7.51	41	5.13	0.0001
2020-11-05	2020-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	13,315	0	0.00	39	-36.07	0.0001
2020-08-12	2020-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	13,315	-3,000	-18.39	61	-1.61	0.0002
2020-05-11	2020-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	16,315	0	0.00	62	1.64	0.0003
2020-02-05	2019-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	16,315	0	0.00	61	-29.07	0.0002
2019-10-30	2019-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	16,315	-1,000	-5.78	86	30.30	0.0004
2019-07-19	2019-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	17,315	-11,500	-39.91	66	-54.79	0.0003
2019-05-13	2019-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	28,815	1,000	3.60	146	175.47	0.0007
2019-02-11	2018-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	27,815	3,500	14.39	53	-41.76	0.0003
2018-11-06	2018-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	24,315	-500	-2.01	91	18.18	0.0004
2018-07-31	2018-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	24,815	0	0.00	77	30.51	0.0004
2018-05-14	2018-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	24,815	0	0.00	59	-39.18	0.0003
2018-02-12	2017-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	24,815	24,815		97		0.0005

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.